This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Rescheduling would stand to have the largest impact on cannabis research and business taxes. Cannabis research The Controlled Substances Act requires scientists to register with the DEA if they want to research Schedule I substances. No matter the reason, we’re here to help you better understand and access medical cannabis.
SPOKANE — Researchers at Washington State University are teaming up with the Puyallup Tribe of Indians in an effort to chart the tribe’s outcomes prescribing medicinal marijuana to patients. This partnership with WSU and Qwibil will help us research the safety and efficacy of cannabis as medicine for our patients’ use.”.
The Office of Drug Control (ODC) issues several license types, including: Cultivation growing cannabis for medicinal or research purposes. Research studying cannabis for medicinal development. Businesses should also investigate potential research and development (R&D) incentives if applicable.
MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Back to our study.
Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies. AI-Powered search platform maximizes access to publications.
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?
Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. RYAH Group Inc.
Before we dive into the research, here’s the lowdown: Important takeaway points on cannabis and cancer Your situation is unique. Advocate for the rescheduling of cannabis to improve access to cannabis for research purposes, and scientific funding for novel cannabinoid-based cancer therapies. 1 So can cannabis cure cancer?
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?
The findings of a new study into cannabis use disorder (CUD) among veterans have been released by a team of researchers from Pennsylvania’s Center of Excellence in Substance Addiction Treatment and Education at the Corporal Michael J. Crescenz VA Medical Center. Their hypothesis was published in the American Journal of Psychiatry.
Veriheal does not support illegally consuming therapeutic substances such as psilocybin but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.
When you walk into a hardware store, pharmacy, or even a liquor store, if you don’t know exactly what product will meet your needs there’s someone educated enough to point you to the right product and the data to back up that recommendation, says Tyler Dautrich, COO of Releaf. Edited and mixed by Michael Schaeffer Omer-Man.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
The obvious reasons for choosing the illicit market over the legal market include the likes of easier accessibility and lower cost. However, Clement states that the manner in which they operate is “actually what should be the models for business development in this industry.” This is a data analysis.” People should copy them.
At the same time, research on medical cannabis over the past two decades has not ceased to increase and provide evidence of the plant’s medical value. As a result, medical and scientific research has been highly constrained for many decades. Exponential Increase in Cannabis Research: Trends.
Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. Gabe@Ehave.com.
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).
On Wednesday, Argentina’s Minister of Productive Development, Matías Kulfas , presented a bill titled, “Regulatory framework for the development of the medical cannabis and hemp industry ,” within the framework of the Economic and Social Council. Supplier development: Genetics, agro 4.0, Yahoo Finance reports.
For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. We are absolutely ecstatic,” George Hodgin, the CEO of the Castroville, California based Biopharmaceutical Research Co. BRC) told The Cannigma this week.
Opponents are likely referencing studies that link mental illness to regular cannabis use, even though those studies have been invalidated by research and do not even revolve around legalization. We found that recreational marijuana access was associated with a 6.29 Support From Other Studies. Singer et al.
In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Exploring the available research on ALS and cannabinoids. As few as 10% of ALS patients live longer than 10 years after being diagnosed.
.–(BUSINESS WIRE)– #cannabis — Dewey Scientific , an agtech innovator pioneering solutions for a sustainable and thriving cannabis industry, announced today the online publication of new data describing the first experimentally validated disease resistance gene in cannabis. Garfinkel, PhD.
A female CEO of a cannabis research company is fighting back against controversial Marijuana investor Andy Defrancesco after he started a twitter campaign to allegedly disparage her company and her personal ethics as a CEO. Read on at … Sol Global Chairman Andy Defrancesco sued for Defamation by Cannabis Research Firm: $SOLCF.
Artificial intelligence is a smarter, faster, and more effective pathway to drug development. With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds major potential to increase the accessibility of drugs and to treat diseases and conditions.
Researchers wanted to evaluate the potential association between cannabis use and respiratory-related emergency room visits and hospitalizations. Data that’s been published on the subject have been contradictory. Not only does the research itself need to be unbiased, but so does the included background information on the subject.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.
This is according to a group of researchers from the University of New Mexico (UNM) , who recently teamed up with the creators of the Releaf App to investigate the true link between cannabis use and energy levels. Data was pulled from 3,922 cannabis self-administration sessions with the help of this application.
Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. Forward-Looking Statement Disclaimer.
The new tool lets individual users and businesses connect with the entire Canxchange universe through a public chat feature, and gives them instant access to the company’s sales and support team. Under a limited access “light” version users can network and accessdata. Two options.
Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. While comfy MRIs are not its primary goal, this psychedelic research has provided solid preliminary evidence that the psychoactive compound found in magic mushrooms can help accomplish just that.
Our NXTecK™ platform is introducing scalable, aggregated, and normalized consumer data with an attribution model, so you know exactly where and how to focus your multi-channel strategies and achieve your digital marketing goals. Free Access to Equio ®. Sponsorship and Marketing Offerings.
Though the distinction between these terms may seem trivial at first glance, it is in fact crucial for cannabis research, and therefore also for consumers and regulators as well. Researchers conducting survey based studies today often only have access to the THC concentration of the cannabis that their participants are using.
This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.
Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.
A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK. LONDON, Aug.
Researchers from Temple University sought to find out how recreational marijuana legalization in Washington and Colorado influenced adolescent treatment admissions for cannabis. Over the past two decades, legal access to marijuana across the United States has been steadily increasing. Researchers Jeremy Mennis and Gerald J.
Producing deep-dive policy and operational research and analysis on priority initiatives. Translating complex policy ideas into talking points, emails, briefs, and other publicly accessible communications. Assist in the research, drafting, and creation of policies for the Supervisor.
is a Canadian company that researches, develops and grows psilocybin-producing mushrooms and functional mushrooms. Ciprick said there needs to be more outcome data and studies on the psilocybin-producing mushrooms to give that comfort level heading forward into introducing a larger market for the product. Optimi Health Corp.
Access to headline, upfront, milestone and royalty data. Access to hundreds of Psychiatry deal contract documents. Comprehensive access to over 780 Psychiatry deal records. Stage of development at signing. Who is responsible for development, supply, and manufacture? Analysis of Psychiatry deal structure.
With over 100 known cannabinoids in cannabis, staying informed about the latest research is crucial for making informed decisions. Understanding how to discern reliable sources, interpret research methodologies, and apply key findings to real-world scenarios can be daunting.
Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Big Data Improves Distribution in the Marijuana Industry. Source: [link]. Global Cannabis Applications Corp.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content